NEW YORK – Three new studies presented at the American Society of Clinical Oncology's virtual annual meeting are highlighting the potential value of Exact Sciences' Oncotype DX Breast Recurrence Score test for helping to determine whether women with hormone receptor positive, HER2-negative breast cancer can avoid the use of neoadjuvant chemotherapy.
One of the studies showed that the test could be especially beneficial in the decision-making process for younger patients in need of neoadjuvant therapy, which could lead to an expanded use of the test.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
"breast" - Google News
May 31, 2020 at 09:45PM
https://ift.tt/2AnWo6Q
Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions - Precision Oncology News
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions - Precision Oncology News"
Post a Comment